Microbot Medical Inc. (NASDAQ:MBOT) Given Average Recommendation of “Buy” by Brokerages

Shares of Microbot Medical Inc. (NASDAQ:MBOT) have been given an average rating of “Buy” by the five brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $6.6250.

Several analysts have issued reports on the company. Zacks Research raised Microbot Medical from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 22nd. HC Wainwright restated a “buy” rating on shares of Microbot Medical in a research note on Tuesday, July 14th. Wall Street Zen raised Microbot Medical from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Loop Capital set a $4.00 target price on Microbot Medical in a research note on Wednesday, June 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Microbot Medical in a report on Wednesday, July 8th.

Institutional Investors Weigh In On Microbot Medical

Several institutional investors have recently bought and sold shares of MBOT. CTC Alternative Strategies Ltd. acquired a new stake in Microbot Medical in the first quarter worth about $28,000. Bank of America Corp DE increased its holdings in shares of Microbot Medical by 1,688.1% during the first quarter. Bank of America Corp DE now owns 75,799 shares of the biotechnology company’s stock valued at $183,000 after acquiring an additional 71,560 shares in the last quarter. Cetera Investment Advisers raised its position in shares of Microbot Medical by 44.7% in the 1st quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 13,099 shares during the last quarter. Private Advisor Group LLC purchased a new position in shares of Microbot Medical in the 1st quarter valued at approximately $54,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Microbot Medical in the 4th quarter worth approximately $65,000. 16.30% of the stock is currently owned by institutional investors and hedge funds.

Microbot Medical Price Performance

Shares of MBOT opened at $1.89 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 21.93 and a current ratio of 22.59. The company has a 50 day moving average price of $1.83 and a 200-day moving average price of $2.07. Microbot Medical has a fifty-two week low of $1.60 and a fifty-two week high of $4.67. The stock has a market capitalization of $126.95 million, a PE ratio of -7.27 and a beta of 1.06.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.03. The business had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.30 million. Equities analysts predict that Microbot Medical will post -0.28 earnings per share for the current fiscal year.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.